Articles | Volume 8, issue 3
https://doi.org/10.5194/jbji-8-175-2023
© Author(s) 2023. This work is distributed under the Creative Commons Attribution 4.0 License.
Original full-length article
| 
28 Jun 2023
Original full-length article |
| 28 Jun 2023
| 28 Jun 2023
Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus
Related authors
J. Bone Joint Infect., 9, 127–136, 2024
J. Bone Joint Infect., 9, 75–85, 2024
J. Bone Joint Infect., 6, 283–293, 2021
Cited articles
Almangour, T. A., Perry, G. K., Terriff, C. M., Alhifany, A. A., and Kaye,
K. S.: Dalbavancin for the management of gram-positive osteomyelitis:
Effectiveness and potential utility, Diagn. Microbiol. Infect. Dis., 93,
213–218, https://doi.org/10.1016/j.diagmicrobio.2018.10.007, 2019.
Appelbaum, P. C.: Reduced glycopeptide susceptibility in
methicillin-resistant Staphylococcus aureus (MRSA), Int. J. Antimicrob. Agents,
30, 398–408, https://doi.org/10.1016/j.ijantimicag.2007.07.011, 2007.
Berend, K. R., Lombardi Jr., A. V., Morris, M. J., Bergeson, A. G., Adams,
J. B., and Sneller, M. A.: Two-stage treatment of hip periprosthetic joint
infection is associated with a high rate of infection control but high
mortality, Clin. Orthop. Relat. Res., 471, 510–518, https://doi.org/10.1007/s11999-012-2595-x,
2013.
Biedenbach, D. J., Ross, J. E., Fritsche, T. R., Sader, H. S., and Jones, R.
N.: Activity of dalbavancin tested against Staphylococcus spp. and
beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse
medical centers in the United States, J. Clin. Microbiol., 45, 998–1004, https://doi.org/10.1128/JCM.02368-06, 2007.
Biedenbach, D. J., Bell, J. M., Sader, H. S., Turnidge, J. D., and Jones, R.
N.: Activities of dalbavancin against a worldwide collection of 81,673
gram-positive bacterial isolates, Antimicrob. Agents Chemother., 53,
1260–1263, https://doi.org/10.1128/AAC.01453-08, 2009.
